ArticleChinese medicine2026
Calculus Bovis ameliorates primary sclerosing cholangitis via a dual-pronged mechanism restoring bile acid and lipid homeostasis in the gut-liver axis.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivePrimary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease lacking FDA-approved therapy. Calculus Bovis (CB), a traditional medicine derived from animal gallstones, has been historically used for treating hepatobiliary diseases, but its therapeutic potential and mechanisms in PSC remain unexplored. This study aimed to investigate the efficacy of CB in an experimental PSC model and elucidate its underlying mechanisms.
methodsA PSC mouse model was induced by a 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet for 4 weeks. Mice were treated with CB (50,100, 150 mg/kg/day) or ursodeoxycholic acid (UDCA, 100 mg/kg/day). Liver injury, fibrosis, intestinal barrier integrity, bile acid (BA) profiles, and lipid levels were assessed. Hepatic and intestinal gene/protein expression related to BA and lipid metabolism was analyzed. Integrated transcriptomics, network pharmacology, and in vitro serum pharmacology were employed to elucidate the underlying mechanisms.
resultsCB administration significantly alleviated liver injury, fibrosis, and intestinal barrier damage in DDC-induced mice. It restored BA homeostasis across the gut-liver axis, normalizing aberrant BA profiles in serum and liver while increasing BA excretion in feces. CB also ameliorated dyslipidemia, reducing hepatic and serum lipid levels. Mechanistically, CB and its bioactive BA components exerted their effects through a dual-pronged mechanism: (1) activation of the SIRT1-PGC-1α axis to transcriptionally upregulate the expression of nuclear receptors FXR and PPARα in the liver and intestine, and (2) direct ligand-dependent activation of FXR and PPARα protein functions. This concerted activation enhanced the transcription of genes involved in BA detoxification, transport, and fatty acid β-oxidation. Inhibition of SIRT1 or antagonism of FXR/PPARα attenuated these protective effects in vitro.
conclusionCB attenuates experimental PSC by modulating BA and lipid homeostasis via the gut-liver axis, mediated through a novel dual mechanism involving SIRT1-PGC-1α pathway activation and direct receptor agonism. These findings not only highlight CB as a promising multi-target agent for PSC treatment, but also provide novel insights into the therapeutic modulation of metabolism in the gut-liver axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.